Trials / Recruiting
RecruitingNCT06862869
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy in China: A Multicenter, Prospective Cohort Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 800 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult patients treated with Alectinib as adjuvant therapy in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alectinib | Participants will have received alectinib adjuvant treatment for resected stage II-IIIB ALK-positive NSCLC in routine clinical practice. NOTE: No intervention will be provided in this study as the study is observational. |
Timeline
- Start date
- 2025-04-30
- Primary completion
- 2028-10-30
- Completion
- 2029-04-30
- First posted
- 2025-03-06
- Last updated
- 2026-04-06
Locations
40 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06862869. Inclusion in this directory is not an endorsement.